Damien Mcdonald Purchases 13,035 Shares of Enovis (NYSE:ENOV) Stock

Enovis Corporation (NYSE:ENOV) CEO Damien Mcdonald purchased 13,035 shares of the business’s stock in a transaction dated Friday, September 4th. The shares were acquired at an average cost of $19.15 per share, for a total transaction of $249,620.25. Following the acquisition, the chief executive officer owned 247,077 shares of the company’s stock, valued at approximately $4,731,524.55. The trade was a 5.57% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Enovis Stock Down 4.2%

ENOV stock opened at $18.58 on Friday. The firm’s 50-day moving average is $25.50 and its two-hundred day moving average is $24.20. The company has a market capitalization of $1.07 billion, a price-to-earnings ratio of -0.96 and a beta of 1.31. Enovis Corporation has a 52 week low of $18.52 and a 52 week high of $34.28. The company has a current ratio of 1.98, a quick ratio of 1.00 and a debt-to-equity ratio of 0.84.

Enovis (NYSE:ENOV) last announced its earnings results on Thursday, August 6th. The company reported $0.90 earnings per share for the quarter, beating the consensus estimate of $0.85 by $0.05. The business had revenue of $582.78 million during the quarter, compared to analysts’ expectations of $581.84 million. Enovis had a positive return on equity of 12.03% and a negative net margin of 47.96%.The company’s quarterly revenue was up 3.2% on a year-over-year basis. During the same quarter last year, the business posted $0.79 earnings per share. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, analysts forecast that Enovis Corporation will post 3.15 earnings per share for the current fiscal year.

More Enovis News

Here are the key news stories impacting Enovis this week:

• Positive Sentiment: CEO Damien McDonald bought 13,035 shares for approximately $249,620, increasing his stake by 5.57%. A substantial open-market purchase by the chief executive may signal confidence that the recent selloff has pushed the stock below its perceived value. SEC filing on CEO purchase
• Positive Sentiment: Insider Oliver Engert purchased 5,140 shares worth approximately $100,024, raising his ownership by 9.16%. The additional insider buying provides another potential confidence signal for investors. SEC filing on insider purchase
• Positive Sentiment: Zacks upgraded Enovis to Rank #2, or “Buy,” citing improving earnings prospects. Analysts’ upward earnings revisions and technically oversold conditions also suggest the possibility of a near-term trend reversal. Zacks Buy rating article
• Positive Sentiment: Canaccord Genuity maintained a Buy rating on ENOV, reinforcing the view that the selloff may have created an attractive entry point. Canaccord Genuity rating article
• Neutral Sentiment: A Q2 comparison with other specialty medical-device companies provides industry context, but the item does not identify a new material change to Enovis’ outlook. Q2 earnings comparison
• Negative Sentiment: Wells Fargo lowered its ENOV price target to $33, while Citizens JMP reduced its target to $47. Although both targets remain above the current trading range, the cuts indicate more cautious valuation assumptions and may weigh on sentiment. Wells Fargo price-target article Citizens JMP price-target article

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the company. BMO Capital Markets set a $27.00 price target on Enovis in a research report on Tuesday. Citigroup restated a “market outperform” rating on shares of Enovis in a research report on Wednesday. Canaccord Genuity Group dropped their target price on Enovis from $50.00 to $45.00 and set a “buy” rating on the stock in a report on Monday, August 17th. BTIG Research reduced their price target on shares of Enovis from $40.00 to $36.00 and set a “buy” rating for the company in a research report on Tuesday. Finally, UBS Group reaffirmed a “buy” rating and set a $51.00 price objective (up from $50.00) on shares of Enovis in a research report on Tuesday, July 28th. Ten investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Enovis presently has an average rating of “Moderate Buy” and an average target price of $40.38.

Institutional Investors Weigh In On Enovis

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. AQR Capital Management LLC grew its position in shares of Enovis by 12.5% in the first quarter. AQR Capital Management LLC now owns 63,671 shares of the company’s stock valued at $2,363,000 after purchasing an additional 7,072 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in Enovis by 37.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 267,617 shares of the company’s stock valued at $10,226,000 after purchasing an additional 73,116 shares during the period. Empowered Funds LLC boosted its stake in Enovis by 13.0% during the 1st quarter. Empowered Funds LLC now owns 6,515 shares of the company’s stock valued at $249,000 after purchasing an additional 749 shares during the period. EverSource Wealth Advisors LLC grew its holdings in Enovis by 125.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock valued at $40,000 after buying an additional 707 shares during the last quarter. Finally, Amundi grew its holdings in Enovis by 24,405.0% in the 2nd quarter. Amundi now owns 9,802 shares of the company’s stock valued at $328,000 after buying an additional 9,762 shares during the last quarter. 98.45% of the stock is currently owned by institutional investors and hedge funds.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.